UNSPSC 51171622: Sodium phosphate

This classification denotes an electrolyte replacement agent with the molecular formula NAH2PO4, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier SE337SVY37, more generally known as sodium phosphate. European Medicines Agency schedules sodium phosphate in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB12587MIG. The term SODIUM PHOSPHATE is an International Non-Proprietary Name or INN. see WHO INN reference publication, Volume 25, no. 10 1971, list 11.

Most nations schedule sodium phosphate under HS 28444030 and SITC 52519. As of Q4 2014, SODIUM PHOSPHATE remains the US FDA Preferred Term for this commodity. Sodium phosphate bears US NLM identifiers UMLS ID C0074757 and NCI Concept Code C29459. SMILES: [O-]P(=O)([O-])[O-].[NA+].[NA+].[NA+].

UNSPSC 51171622 Sodium phosphate is a Commodity code that in recent state and local procurement activity covers active pharmaceutical ingredients and finished drugs used in drug testing, pharmacy benefit management, and pharmaceutical supply chain operations. State and local governments procure under this code through county health and corrections departments, state health and human services agencies, and multistate cooperative purchasing consortia. The scope of work spans laboratory reagents and screening chemicals for specimen testing, generic pharmaceuticals for state employee health plans and Medicaid programs, and direct-to-manufacturer pharmaceutical supply agreements. Collin County Community Supervision and Corrections Department's offender drug testing RFP illustrates the chemical testing dimension—the procurement calls for immunoassay screening and confirmation testing using LC/MS/MS or GC/MS methodology with ancillary testing methodologies including oral fluid and hair analysis, all requiring lab-grade reagents and consumables to support approximately 25,031 annual tests across two collection sites in the Dallas-Fort Worth area.

Recent activity concentrates in Texas and Minnesota. Texas Health and Human Services Commission issued an RFI in April 2026 exploring direct-to-manufacturer pharmacy programs, signaling state interest in reshaping pharmaceutical procurement outside traditional benefit manager channels. The Minnesota Multistate Cooperative Purchasing Alliance (MMCAP), administered by the Minnesota Department of Administration's Office of State Procurement, issued an RFP in January 2026 with a March 26, 2026 response deadline for generic multi-source pharmaceuticals and OTC products to be supplied through AmerisourceBergen, Cardinal Health, and Morris & Dickson to state and local facilities in Minnesota and Oregon, with contract term commencing July 1, 2026. Collin County's $600,000 two-year drug testing RFP is due July 23, 2026 with an anticipated award date of August 10, 2026. The mix of issuing bodies—county corrections, state HHS agencies, and regional cooperative consortia—suggests fragmented procurement authority with no single dominant buyer, though cooperative purchasing vehicles appear to be consolidating demand across multiple jurisdictions.